Bio News

The U.S. government has reached most-favored-nation (MFN) drug-pricing agreements with nine midsize pharmaceutical companies. Alcon, Astellas, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB participated in the agreements. The companies pledged to invest at least $19.6 billion (approximately 27 trillion won) in U.S. production.

BIOBOOK TEAM
biobookmedia@biobook.co.krAsahi Kasei Wins FDA Approval for New Herpes Drug Hovlpri for Immunocompromised Adults
Mirum’s Livmarli succeeds in phase 3 trial, company seeks expanded indication for rare liver disease
Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count